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Abstract
Chronic urticaria (CU) has a major effect on patients’ quality of life. While there have been progressive advances
regarding its pathogenesis and treatment, much remains to be done.
Registries of other chronic non-communicable diseases have shown many benefits, such as additional basic
knowledge and management approaches to diabetes mellitus. Standards of care as well as diagnostic approaches
can be elaborated and compared from different sites, using validated instruments. Registries in allergic diseases are
also becoming well recognized, and the first registry on CU, accessible from SLaai’s webpage, includes parameters
for identification, evaluation and management. In our vision, informatics strategies have the potential to improve
care for chronic illnesses such as CU. The registry represents a valid instrument from which to obtain a sufficient
sample size for epidemiological studies and/or clinical research planning, including feasibility and potential
enrollment. It can also provide invaluable data for adapting guidelines to local populations, as well as diagnostic
approaches and cost-effective interventions in the context of organizational efforts to improve patient care.
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Why CU represents a major health problem?
Urticaria is characterized by wheals and flares, with or
without angioedema, presenting a wide spectrum of
severity. Considered a frequent disease, its prevalence
has been reported from less than 1% to over 10%, and it
is estimated that 20% of the population will suffer an
urticarial episode sometime in their life [1, 2]. In chil-
dren, the prevalence was reported to be about 5% [3].
Urticaria is generally classified by its duration, i.e.
acute if lasting < 6 weeks, or chronic when lasting more
than 6 weeks. Chronic urticaria involves two primary
subgroups according to whether symptoms occur spon-
taneously (Chronic Spontaneous Urticaria - CSU) or is
induced by a demonstrable stimulus (Chronic Inducible
Urticaria - CIU), and individual conditions are described
according to their underlying etio-pathology or pur-
ported mechanism of induction [4]. Considering patients
with no identifiable stimulus, about 10% have circulating
IgG anti-IgE and 30 to 40% have IgG antibody to the
alpha subunit of the IgE receptor. However, more than
half of patients lack of these autoantibodies. In either
case the disorder is now called chronic spontaneous ur-
ticaria [2].
CSU and other chronic forms of urticaria adversely
affect performance at work and school, decrease quality
of life, and belong then, to the group of severe “allergic”
diseases [1, 5].
Second-generation antihistamines are the mainstay of
pharmacological treatment in adults and children, aimed
at relief of symptoms, with dose adjustment for pediatric
use. However, gaining control of symptoms with anti-
histamines is achieved in less than half of patients with
regular doses, with a limited improvement of this propor-
tion with four fold regular doses [6, 7]; hence a substantial
need for new therapeutic strategies emerges. Addition of
LTR antagonists or changing anti H1 receptor antagonists
plus short cycles of steroids are commonly considered
when insufficient control is obtained; but ultimately the
treatment involves the use of immune-modulators like
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those refractory situations [6–9]. Because of the potential
side effects of steroids, cyclosporine and dapsone, anti IgE
biological therapy (omalizumab) has emerged as an effect-
ive and safe alternative. Omalizumab reduces free IgE
levels, and decreases responsiveness to stimuli acting
through the IgE receptor, reverses blood basopenia, and
limits recruitment of basophils into skin lesions [10, 11].
It may emerge as the agent of choice for patients refrac-
tory to anti histamines [12].
The lack of control in a remarkable proportion of
these chronic patients evidences many unmet needs re-
garding its patho-physiology and treatment [6, 7].
Why a registry?
Registries from real life patients and databases constitute
key instruments to develop health policies, diagnosis and
treatment guidelines, and clinical research in order to
provide the best patient care.
They are valuable tools with the potential to transform
the way chronic diseases are approached. To date, little
work has been done to determine how a chronic disease
registry could improve patient management. Some suc-
cessful initiatives have been reported; diabetes is an ex-
ample [13].
There is an endless opportunity for the exchange of
health information that could be developed. Computer-
ized registries offer the possibility to identify both com-
mon characteristics and differences in the magnitude of
the illness and its natural history. The severity and
quality of life involvement, and the efficacy of recom-
mended treatment and any undesirable side effects can
be catalogued. Chronic conditions are ideal subjects to
be explored.
Development of registries could potentially help to
determine standards of care. In 2007, Young et al. per-
formed a systematic review on the usefulness of having
clinical information integrated; the main recommenda-
tion was that interactive (disorder-specific) pathways
should be implemented to quickly provide clinicians
with patient clinical status, treatment history, and deci-
sion support [14].
A European initiative to register patients receiving or-
phan drugs provides needed data on efficacy and safety
since marketing authorization is usually obtained with
necessary but incomplete evidence. A specific report col-
lected by Orphanet is available on the web [15].
Registries in Allergology provided of valuable informa-
tion, quite difficult to obtain with other methodologies.
A nice example is the online survey on anaphylaxis in
Latin America (OLASA), which evidenced that half of
patients, did not have access to immediate treatment for
anaphylaxis, and also fewer than 40% of patients have re-
ceived epinephrine, just to mention some of the remark-
able information obtained from this registry [16].
Another valuable registry is the Drug Allergy and
Hypersensitivity Database, evaluating patients having
undergone a standardized procedure on drug intoler-
ance. Information like a low risk when administering
cefuroxime in B lactams’ sensitive patients is one ex-
ample, as well as additional evaluations on side chain
cross reactions [17].
What should a CU registry include?
As urticaria is a heterogeneous group of diseases, im-
portant CU features must be considered. The definition
of each type of urticaria, as well as tools employed for
diagnosis must provide easy access to the investigator.
In typical chronic spontaneous urticaria, wheals arise
spontaneously with no identified stimuli. While parasite
infection may be a significant association in some coun-
tries, the presence of eosinophilia should lead to a stool
analysis for ova and parasites, at minimum. Otherwise
patients presenting with chronic spontaneous urticaria
with a normal physical exam and no other suggestive
complaints should not be evaluated for food allergy or
occult infections [18].
In order to evaluate disease activity and response to
treatment, validated scoring systems like the urticaria ac-
tivity score should be used [19].
Psychological stress can exacerbate CSU symptoms,
even though it is not a cause, and at least in some pa-
tients taking this fact into account may be important
for the management [20–22]. Health Related Quality of
Life (HRQL) is increasingly used in epidemiological
studies, with a paramount importance in chronic condi-
tions. Validated CSU specific questionnaires should be
implemented and they are available in different lan-
guages [23–26]. CSU has a detrimental effect on both
objective functioning and subjective well - being com-
parable to those reported from patients with coronary
artery disease, and both health status and subjective satis-
faction are lower than in respiratory diseases [27, 28].
Efficacy and side effects of prescribed treatment
should also be assessed since there are still many unmet
needs [1, 6].
CU first registry
The Libra and Ayre Foundations from Argentina are de-
voted to research and education regarding allergic diseases.
Their members developed and provide the maintenance of
an electronic database registry for CU that was made avail-
able to SLaai authorities for its dissemination, as part of
the activities offered to their members, in Spanish.
The present initiative was granted from the declared
foundations to SLaai, being guided by its Scientific Sec-
retary. Data is owned by SLaai’s Scientific Secretariat,
and is entered by any identified allergologist from the
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region. All allergologists from Latin America willing to
participate are invited.
The scientific board is formed by two members from
Executive Committee (one is the Scientific Secretary), a
member from Urticaria Scientific Committee and four
external advisory board persons (authors).
About ethics approval, notwithstanding regulation
concerning observational retrospective research exempt
from IRB/IEC approval (Eg 10.1093/ije/dyp164), two
independent ethics committees were consulted (Medical
Council of Salta & Clinical Studies Foundation of
Buenos Aires, Argentina). Both did agree on the
unnecessary written informed consent, based on the
minimum risk of the proposed project. However, one of
them suggested informing the patient on the initiative
and the anonymous feature of the registry if seen, just
like it is stated in the web page.
Two non-governmental non-profit foundations (Ayre
& Libra) supported database development and mainten-
ance of it. No funding for authors or participants was
provided. There is no role of the industry at all.
The initiative is supported by the Latin American
Society of Allergy, Asthma and Immunology, and no
other support or endorsement was searched by now.
The present registry (accessible through SLaai’s web-
page as Registro Iberoamericano de Urticaria Crónica
Espontánea) involves several aspects of CU identifica-
tion, evaluation and management [29].
Sections were developed considering key elements for
electronic surveys, and how the outcomes could be
interpreted [30]. Once available, validated instruments
like UAS7 and CU-Q2oL were used [19, 26].
It begins with criteria for patient eligibility for the
registry. If acceptable, demographic data of patients and
the reporting physicians are registered.
The next section deals with CU time elapsed, identifi-
cation of triggers and severity of symptoms, followed by
information regarding quality of life aspects reported by
patients.
Then, all laboratory measurements available are tabu-
lated and clinical evaluations performed.
Finally, interventional strategies as well as efficacy and
side effects of treatments prescribed are reviewed.
The full content of the registry accessed on line is
available as Additional file 1. It is a cross sectional
registry, looking for all the information available to
assisting physician, and does not intend to follow up
treatment efficacy or evolution of the variables reported.
The present registry is completely anonymous for
patients and blinded for participants, with just two
persons (investigators who developed the database)
having access to the collected data. Once the data
collection is considered appropriate and closed (esti-
mated in over two hundred reports), principal
investigators will maintain a secured copy and the
registry will be deleted.
A potential limitation on the present registry is the
generalization of these data, obtained from patients
assisted by Latin American allergologists. This limitation
could also highlight some particular characteristics to be
compared with non-Latin American populations, as well
as the potential differences between Latin American
countries.
Even recognizing that there is no standardized ap-
proach for these patients, the present registry does not
intend to provide one. Instead, it is devoted to search for
peculiarities and common features, with the potential to
find pitfalls or unmet needs from current available
guidelines about CU diagnostic methods and manage-
ment in the present population.
By the time this initiative was developed and commu-
nicated, it was the first to our knowledge. However, the
CURE project available now at http://www.urticaria-
registry.com evidenced similarities of variables such as
characteristics of patients having CU, causal factors,
related triggers, treatment response and some quality of
life parameters. The differences compared to the present
registry (a cross sectional one from retrospective data)
are not searching for duration and course of disease, dis-
ease activity, quality of life impairment, absence from
school or work and health care costs.
Conclusions
In our vision, informatics strategies have the potential to
improve care for chronic illnesses such as CU. Registries
usefulness is well recognized in allergic diseases [31],
and the present registry represents a valid instrument
from which to obtain a sufficient sample size for epi-
demiological studies and/or clinical research planning,
including feasibility and potential enrollment. It can also
provide invaluable data for adapting guidelines to local
populations, as well as diagnosis approach and cost-
effective interventions in the context of organizational
efforts to improve patient care.
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